Designing early detection programs for ovarian cancer.
Hartge
Patricia
P
D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D055088:Early Detection of Cancer; D030501:Epididymal Secretory Proteins / Q000378:metabolism; D005260:Female; D058851:GPI-Linked Proteins; D019398:Genes, BRCA1; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000379:methods*; D008562:Membrane Glycoproteins / Q000097:blood; D000090204:Mesothelin; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D011237:Predictive Value of Tests; D014481:United States / Q000453:epidemiology; D023083:beta-Defensins
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C426184:DEFB126 protein, human; D030501:Epididymal Secretory Proteins; D058851:GPI-Linked Proteins; D008562:Membrane Glycoproteins; D023083:beta-Defensins; D000090204:Mesothelin